ALMKT:EPA
Mauna Kea Technologies SA
0,14 €
0,00%
(0,00) 1D
1-окт., 17:35:10 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
0,14 €
High
0,14 €
Low
0,13 €
Mkt. cap
28,81 млн
Avg. vol.
416,28 миң
Volume
308,80 миң
P/E ratio
1,15
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 млн
No. of employees
59
Open
0,14 €
High
0,14 €
Low
0,13 €
Mkt. cap
28,81 млн
Avg. vol.
416,28 миң
Volume
308,80 миң
P/E ratio
1,15
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 млн
No. of employees
59
News stories
From web sources and news partners
roundtable.io
·
40 мүнөт мурун
TOKEN2049 Singapore brings Nasdaq's CEO, F1 Champions, and crypto's biggest founders under one roof
Pulse 2.0
·
48 мүнөт мурун
Vylor Completes Corteva Spin-Off And Begins Trading On NYSE
GlobeNewswire
·
1 саат мурун
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Yahoo Finance
·
19 мүнөт мурун
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA